Vanguard Group Inc. raised its position in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) by 4.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,848,748 shares of the biopharmaceutical company’s stock after buying an additional 302,986 shares during the period. Vanguard Group Inc. owned about 0.06% of Keryx Biopharmaceuticals worth $42,188,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Stifel Financial Corp raised its position in Keryx Biopharmaceuticals by 11.5% in the first quarter. Stifel Financial Corp now owns 33,736 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 3,478 shares during the last quarter. Shufro Rose & Co. LLC raised its position in Keryx Biopharmaceuticals by 0.7% in the first quarter. Shufro Rose & Co. LLC now owns 73,200 shares of the biopharmaceutical company’s stock worth $451,000 after buying an additional 500 shares during the last quarter. Iridian Asset Management LLC CT raised its position in Keryx Biopharmaceuticals by 16.0% in the first quarter. Iridian Asset Management LLC CT now owns 265,110 shares of the biopharmaceutical company’s stock worth $1,633,000 after buying an additional 36,540 shares during the last quarter. Parametric Portfolio Associates LLC raised its position in Keryx Biopharmaceuticals by 60.1% in the first quarter. Parametric Portfolio Associates LLC now owns 192,982 shares of the biopharmaceutical company’s stock worth $1,189,000 after buying an additional 72,436 shares during the last quarter. Finally, Advantage Investment Management LLC raised its position in Keryx Biopharmaceuticals by 20.0% in the first quarter. Advantage Investment Management LLC now owns 65,690 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 10,934 shares during the last quarter. 57.06% of the stock is currently owned by institutional investors and hedge funds.

Shares of Keryx Biopharmaceuticals, Inc. (KERX) traded up 1.10% on Friday, reaching $6.42. The company’s stock had a trading volume of 950,163 shares. The firm’s 50 day moving average is $7.24 and its 200-day moving average is $6.15. The stock’s market cap is $762.38 million. Keryx Biopharmaceuticals, Inc. has a 52-week low of $4.03 and a 52-week high of $8.38.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.60. Keryx Biopharmaceuticals had a negative return on equity of 2,902.87% and a negative net margin of 431.89%. The firm had revenue of $15.10 million for the quarter, compared to the consensus estimate of $14.51 million. During the same period last year, the firm earned ($0.42) EPS. The company’s revenue for the quarter was up 62.4% on a year-over-year basis. On average, equities research analysts forecast that Keryx Biopharmaceuticals, Inc. will post ($1.23) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Keryx Biopharmaceuticals, Inc. (KERX) Stake Increased by Vanguard Group Inc.” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.dailypolitical.com/2017/08/13/keryx-biopharmaceuticals-inc-kerx-stake-increased-by-vanguard-group-inc.html.

A number of research analysts recently weighed in on the company. Zacks Investment Research raised Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 target price on the stock in a report on Wednesday, July 12th. BidaskClub lowered Keryx Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Morgan Stanley reissued an “equal weight” rating and set a $7.00 target price (up from $4.00) on shares of Keryx Biopharmaceuticals in a report on Tuesday, July 25th. Maxim Group set a $9.00 target price on Keryx Biopharmaceuticals and gave the stock a “buy” rating in a report on Thursday, July 27th. Finally, Cowen and Company reaffirmed a “market perform” rating on shares of Keryx Biopharmaceuticals in a report on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $7.48.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Want to see what other hedge funds are holding KERX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX).

Institutional Ownership by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.